Citius Oncology, Inc. SEC filings CTOR
Citius Oncology, Inc. has 268 filings in SEC EDGAR's recent list, going back to May 19, 2021. Its latest annual report, Form ARS, was filed on Aug 26, 2026 for the period ended Sep 30, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (other events). The company's fiscal year ends on September 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Other events
|
Oct 23, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 29, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2026 | Aug 14, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 12, 2026 | Aug 7, 2026 |
| 8-K |
Current report
Other events
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Other events
|
Jun 1, 2026 | Jun 1, 2026 |
| 8-K |
Current report
Results of operations
|
May 15, 2026 | May 15, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Other events
|
May 6, 2026 | May 4, 2026 |
| 8-K |
Current report
Other events
|
Apr 29, 2026 | Apr 29, 2026 |
| 8-K |
Current report
Listing notice
|
Apr 28, 2026 | Apr 22, 2026 |
| 8-K |
Current report
Other events
|
Mar 31, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Other events
|
Mar 10, 2026 | Mar 10, 2026 |
| 8-K |
Current report
Other events
|
Mar 4, 2026 | Mar 4, 2026 |
| 8-K |
Current report
Results of operations
|
Feb 13, 2026 | Feb 13, 2026 |
| 8-K |
Current report
Results of operations
|
Dec 23, 2025 | Dec 23, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Dec 10, 2025 | Dec 8, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 1, 2025 | Dec 1, 2025 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Oct 27, 2025 | Oct 27, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 23, 2025 | Oct 23, 2025 |
| 8-K |
Current report
Unregistered share sale, Officer or director change
|
Sep 19, 2025 | Sep 19, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Sep 10, 2025 | Sep 9, 2025 |
| 8-K |
Current report
Other events
|
Aug 18, 2025 | Aug 18, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2025 | Aug 12, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Jul 18, 2025 | Jul 16, 2025 |
| 8-K |
Current report
Other events
|
Jun 27, 2025 | Jun 26, 2025 |
| 8-K |
Current report
Other events
|
Jun 17, 2025 | Jun 17, 2025 |
| 8-K |
Current report
Results of operations
|
May 14, 2025 | May 14, 2025 |
| 8-K |
Current report
Listing notice
|
Apr 25, 2025 | Apr 23, 2025 |
| 8-K |
Current report
Material agreement
|
Apr 3, 2025 | Mar 28, 2025 |
| 8-K |
Current report
Other events
|
Feb 14, 2025 | Feb 14, 2025 |
| 8-K |
Current report
Other events
|
Feb 6, 2025 | Feb 6, 2025 |
| 8-K |
Current report
Other events
|
Jan 7, 2025 | Jan 7, 2025 |
| 8-K |
Current report
Other events
|
Jan 6, 2025 | Jan 6, 2025 |
| 8-K |
Current report
Results of operations
|
Dec 27, 2024 | Dec 27, 2024 |
| 8-K |
Current report
Other events
|
Nov 12, 2024 | Nov 11, 2024 |
| 8-K |
Current report
Material agreement
|
Sep 13, 2024 | Sep 9, 2024 |
| 8-K |
Current report
Other events
|
Sep 5, 2024 | Sep 5, 2024 |
| 8-K/A |
Amended current report
Acquisition or sale of assets
|
Aug 26, 2024 | Aug 12, 2024 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change to shareholder rights, Auditor change, Change in control, Officer or director change, Bylaw or fiscal year change
|
Aug 16, 2024 | Aug 12, 2024 |
| 8-K |
Current report
Officer or director change, Shareholder vote results, Other events
|
Aug 5, 2024 | Aug 2, 2024 |
| 8-K |
Current report
Material agreement, New debt
|
Jul 19, 2024 | Jul 17, 2024 |
| 8-K |
Current report
Material agreement, New debt
|
Jun 18, 2024 | Jun 17, 2024 |
| 8-K |
Current report
Other events
|
Jun 6, 2024 | May 31, 2024 |
| 8-K |
Current report
Material agreement, New debt
|
May 21, 2024 | May 17, 2024 |
| 8-K |
Current report
Material agreement, New debt
|
Apr 29, 2024 | Apr 26, 2024 |
| 8-K |
Current report
Material agreement, New debt, Bylaw or fiscal year change, Shareholder vote results, Other events
|
Jan 18, 2024 | Jan 17, 2024 |
| 8-K |
Current report
Other events
|
Jan 10, 2024 | Jan 10, 2024 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Oct 24, 2023 | Oct 23, 2023 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Other events
|
Oct 18, 2023 | Oct 18, 2023 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Other events
|
Jul 18, 2023 | Jul 18, 2023 |
| 8-K |
Current report
Other events
|
Dec 6, 2022 | Dec 6, 2022 |
| 8-K |
Current report
Other events
|
Oct 24, 2022 | Oct 24, 2022 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Bylaw or fiscal year change, Other events
|
Oct 19, 2022 | Oct 13, 2022 |
Showing 55 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CTOR (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- DE
- Headquarters
- Cranford, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1851484
- Former names
- TenX Keane Acquisition (until Aug 5, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.